Although IL-1β inhibition increases expression of the pancreatic β-cells in T2DM patients[13], the present study reported only two hypoglycaemic events with medium-dose canakinumab (versus one on placebo), which were mild-to-moderate in severity and none was suspected by the investigators to be related to the study drug. This evidence concerns the gene IL1B and type 2 diabetes mellitus.